Eye scan imaging to look for Alzheimer's-related protein deposits in people with memory problems
Tests an eye scan for Alzheimer's-related changes in adults with memory problems.
Plain-language title generated from the registry record
Registry title: A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's Disease
Key facts
- Where
- Abu Dhabi, United Arab EmiratesSee the 3 sites
Where in United Arab Emirates
- Burjeel Medical CityAbu Dhabi, United Arab EmiratesNot yet recruiting
- Sheikh Shakhbout Medical CityAbu Dhabi, United Arab EmiratesTaking people
- Sheikh Tahnoon Bin Mohammed Medical CityAbu Dhabi, United Arab EmiratesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07254234
- Record updated
- 24 September 2026
- Original description
The purpose of this study is to test the use of a screening tool to detect changes in the eye that are associated with Alzheimer's disease in adult participants with memory issues. For each participant, the study will last up to one month and requires one visit to the research site.Read full original descriptionShow less
Exploratory Study to Assess Utility of RetiSpec Artificial Intelligence Powered Retinal Imaging Solution in Detecting Amyloid Pathology in United Arab Emirates Nationals With Mild Impairment of Cognition
The purpose of this study is to test the use of a screening tool to detect changes in the eye that are associated with Alzheimer's disease in adult participants with memory issues. For each participant, the study will last up to one month and requires one visit to the research site.
Inclusion: Participants who are overtly healthy as determined by medical evaluation, including medical history and physical examination; Have mild memory complaints or a diagnosis of mild cognitive impairment; Have undergone genotyping for apolipoprotein E (APOE) and are willing to make results available to the investigator; Montreal Cognitive Assessment (MoCA) score of greater than or equal to 22 and less than or equal to 28.
Exclusion: Current or previous treatment with anti-amyloid medications; Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study; Have any medical condition that, in the opinion of the investigator, would be a contraindication to participation in the study; Have an existing diagnosis of AD or other dementia; Have contradictions to or an allergy to the ophthalmic dilating agents; Have known diagnosis of severe glaucoma or severe cataracts; have a significant refractive error (more than 12 diopters [D] of spherical equivalent refraction); or have any ocular media opacity that prevents imaging of the retina (that is, severe cataract). Note: mild to moderate cataracts or vision correction with glasses or contact lenses are not exclusion criteria.